Inotiv Inc., a contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has greatly expanded its capacity to conduct Good Laboratory Practices (“GLP”) studies for in vitro cytogenetics and bacterial mutation assays as components of the Standard Battery of genetic toxicology studies required to support first-in-human evaluations of novel therapeutics.   Since acquiring key genetic tox...